Cover Image
市場調查報告書

嗜酸性粒細胞性食道炎:全球臨床實驗檢討

Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 240613
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
嗜酸性粒細胞性食道炎:全球臨床實驗檢討 Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016
出版日期: 2016年11月30日 內容資訊: 英文 68 Pages
簡介

本報告提供嗜酸性粒細胞性食道炎相關之臨床研究最新趨勢分析,提供您疾病·治療方法概要,及G7·E7各國的臨床實驗狀況,各地區、Phase、階段別進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,並彙整有潛力的藥劑比較等資訊。

簡介

  • 嗜酸性粒細胞性食道炎
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 主要國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美

G7各國的臨床實驗數量:嗜酸性粒細胞性食道炎臨床實驗數量上消化管疾病臨床實驗數量所佔的比例

Phase別臨床實驗數量:G7各國

G7各國的臨床實驗數量:Phase別

Phase別臨床實驗數量

  • Phase別的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

未完成的臨床實驗

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 嗜酸性粒細胞性食道炎治療藥

有潛力的藥劑

臨床實驗簡介

  • 有代表性的企業臨床實驗概要
    • Sanofi
    • Regeneron Pharmaceuticals, Inc.
    • Shire Plc
    • Teva Pharmaceutical Industries Limited
    • GlaxoSmithKline plc
    • Oxagen Limited
    • Novartis AG
    • Medpace, Inc.
    • AstraZeneca PLC
    • Actavis plc
  • 有代表性的研究機關/醫院臨床實驗概要
    • Mayo Clinic
    • Cincinnati Children's Hospital Medical Center
    • Academic Medical Center
    • Swiss EE Study Group
    • Azienda Universitaria Policlinico Umberto I di Roma
    • Baylor College of Medicine
    • Children's Hospital Medical Center of Akron
    • Dallas VA Medical Center
    • Medical College of Wisconsin
    • Murdoch Childrens Research Institute

5大臨床實驗簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3922CTIDB

GlobalData's clinical trial report, "Eosinophilic Esophagitis Global Clinical Trials Review, H2, 2016" provides an overview of Eosinophilic Esophagitis clinical trials scenario. This report provides top line data relating to the clinical trials on Eosinophilic Esophagitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 3
  • Report Guidance 4
  • Clinical Trials by Region 5
  • Clinical Trials and Average Enrollment by Country 6
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 8
  • Top Five Countries Contributing to Clinical Trials in Europe 9
  • Top Countries Contributing to Clinical Trials in North America 10
  • Clinical Trials by G7 Countries: Proportion of Eosinophilic Esophagitis to Gastrointestinal Clinical Trials 11
  • Clinical Trials by Phase in G7 Countries 12
  • Clinical Trials in G7 Countries by Trial Status 13
  • Clinical Trials by Phase 14
  • In Progress Trials by Phase 15
  • Clinical Trials by Trial Status 16
  • Clinical Trials by End Point Status 17
  • Subjects Recruited Over a Period of Time 18
  • Clinical Trials by Sponsor Type 19
  • Prominent Sponsors 20
  • Top Companies Participating in Eosinophilic Esophagitis Therapeutics Clinical Trials 21
  • Prominent Drugs 23
  • Latest Clinical Trials News on Eosinophilic Esophagitis 24
  • Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses 24
  • Clinical Trial Profile Snapshots 25

Appendix 65

  • Abbreviations 65
  • Definitions 65
  • Research Methodology 66
  • Secondary Research 66
  • About GlobalData 67
  • Contact Us 67
  • Disclaimer 67
  • Source 68

List of Tables

List of Tables

  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials by Region, 2016* 5
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 8
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 9
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, North America, Top Countries, 2016* 10
  • Proportion of Eosinophilic Esophagitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 11
  • Eosinophilic Esophagitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 12
  • Eosinophilic Esophagitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 13
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials by Phase, 2016* 14
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 15
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 16
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 17
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 18
  • Eosinophilic Esophagitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 19
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 20
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 22
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 23

List of Figures

List of Figures

  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 8
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 9
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10
  • Proportion of Eosinophilic Esophagitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 11
  • Eosinophilic Esophagitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 12
  • Eosinophilic Esophagitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 13
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 14
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 15
  • Eosinophilic Esophagitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 16
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 17
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 18
  • Eosinophilic Esophagitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 19
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 20
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 21
  • Eosinophilic Esophagitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 23
  • GlobalData Methodology 66
Back to Top